WEST LAFAYETTE, IN--(Marketwire - May 13, 2010) - Bioanalytical Systems, Inc. (NASDAQ: BASI) today announced that its Board of Directors named Anthony S. Chilton, Ph.D., as its President and Chief Executive Officer. Dr. Chilton had previously served as Chief Operating Officer since December 1, 2008 and interim President since January 27, 2010.
Dr. Chilton has over 30 years of experience as a scientist and executive in leading life sciences companies in England, Canada and the United States. He joined BASi in December 2008. Prior to joining BASi, Dr. Chilton was in charge of early development programs at Atherogenics, Inc. of Alpharetta, Georgia and provided consulting and advisory services to various pharmaceutical companies. Prior to that, he was Vice President of the Biopharmaceutical Development Division of Cardinal Health Inc., which he joined through a predecessor company in 1998 that was acquired by Cardinal in 2002. Previously, Dr. Chilton spent three years with life sciences companies in Canada, prior to which he held positions in his native United Kingdom. Dr. Chilton received his bachelor's degree in Chemistry from the University of East Anglia in 1981, and his Ph.D. in Analytical Chemistry from the University of Hertfordshire in 1993.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASInc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and
uncertainties including, but not limited to, those market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
